中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
12期
91-92
,共2页
重组人脑利钠肽%充血性心力衰竭%临床疗效
重組人腦利鈉肽%充血性心力衰竭%臨床療效
중조인뇌리납태%충혈성심력쇠갈%림상료효
Recombinant human brain natriuretic peptid%Congestive heart failure%Clinical efficacy
目的：探析重组人脑利钠肽治疗充血性心力衰竭的临床疗效。方法随机选取该院2013年1月-2014年12月收治的120例充血性心力衰竭患者，回顾性分析其临床资料，在患者知情同意的情况下将其分为治疗组和对照组，治疗组采取重组人脑利钠肽进行治疗，对照组采取常规的治疗方法，对比分析两组患者的治疗效果。结果治疗前后两组患者的LVWP、LVD、HR显著降低，LVEF显著升高，治疗组患者的LVWP、LVD、HR及LVEF较对照组比较差异有统计学意义(P<0.05)；治疗组患者总有效率为91.67%较对照组66.67%差异具有统计学意义(P<0.05)；治疗组患者不良反应发生率为3.33%较对照组8.34%，差异有统计学意义(P<0.05)。结论重组人脑利钠肽治疗充血性心力衰竭的临床疗效显著，不良反应少，有效率高，安全性好，值得应用。
目的：探析重組人腦利鈉肽治療充血性心力衰竭的臨床療效。方法隨機選取該院2013年1月-2014年12月收治的120例充血性心力衰竭患者，迴顧性分析其臨床資料，在患者知情同意的情況下將其分為治療組和對照組，治療組採取重組人腦利鈉肽進行治療，對照組採取常規的治療方法，對比分析兩組患者的治療效果。結果治療前後兩組患者的LVWP、LVD、HR顯著降低，LVEF顯著升高，治療組患者的LVWP、LVD、HR及LVEF較對照組比較差異有統計學意義(P<0.05)；治療組患者總有效率為91.67%較對照組66.67%差異具有統計學意義(P<0.05)；治療組患者不良反應髮生率為3.33%較對照組8.34%，差異有統計學意義(P<0.05)。結論重組人腦利鈉肽治療充血性心力衰竭的臨床療效顯著，不良反應少，有效率高，安全性好，值得應用。
목적：탐석중조인뇌리납태치료충혈성심력쇠갈적림상료효。방법수궤선취해원2013년1월-2014년12월수치적120례충혈성심력쇠갈환자，회고성분석기림상자료，재환자지정동의적정황하장기분위치료조화대조조，치료조채취중조인뇌리납태진행치료，대조조채취상규적치료방법，대비분석량조환자적치료효과。결과치료전후량조환자적LVWP、LVD、HR현저강저，LVEF현저승고，치료조환자적LVWP、LVD、HR급LVEF교대조조비교차이유통계학의의(P<0.05)；치료조환자총유효솔위91.67%교대조조66.67%차이구유통계학의의(P<0.05)；치료조환자불량반응발생솔위3.33%교대조조8.34%，차이유통계학의의(P<0.05)。결론중조인뇌리납태치료충혈성심력쇠갈적림상료효현저，불량반응소，유효솔고，안전성호，치득응용。
Objective To explore the clinical effect of recombinant human brain natriuretie peptide (rhBNP) on congestive heart failure. Methods Our hospital in January 2013-2014 December treated 120 cases of congestive heart failure patients, a retrospec-tive analysis of the clinical data, in the case of patients with informed consent will be divided into a treatment group and the con-trol group, the treatment group received recombinant human brain natriuretic peptide treatment, the control group received conven-tional treatment methods, comparative analysis of the two groups of patients with the therapeutic effect. Results Two groups of pa-tients before and after treatment LVWP, LVD, HR was significantly lower, LVEF significantly higher in patients treated with LVWP, LVD, HR and LVEF than in the control group were significantly different, P<0.05 statistically significant;there are always treated patients efficiency91.67% compared with the control group 66.67% difference was significant, P<0.05 statistically signifi-cant;adverse reactions in patients treated with incidence3.33%compared with the control group8.34%difference was significant, P<0.05 considered statistically significant. Conclusion The clinical efficacy of recombinant human brain natriuretic peptide treatment of congestive heart failure was significantly less adverse reactions, high efficiency, safety, deserve applications.
